NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect

Herein, we investigated therapeutic potential of a novel histone lysine demethylase 1 (LSD1) inhibitor, NCL1, in prostate cancer. Hormone-sensitive prostate cancer cells, (LNCaP) and castration resistant cancer cells (PC3 and PCai1) were treated with NCL1, and LSD1 expression and cell viability were...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Etani, Toshiki, Suzuki, Takayoshi, Naiki, Taku, Naiki-Ito, Aya, Ando, Ryosuke, Iida, Keitaro, Kawai, Noriyasu, Tozawa, Keiichi, Miyata, Naoki, Kohri, Kenjiro, Takahashi, Satoru
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2014
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4413623/
https://ncbi.nlm.nih.gov/pubmed/25605246
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki